1 / 6

Prostatitis Therapeutics Pipeline - Phase III Drug Candidate Is Expected to Commercialize in The Coming Years

Prostatitis Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights.

NidhiNehani
Download Presentation

Prostatitis Therapeutics Pipeline - Phase III Drug Candidate Is Expected to Commercialize in The Coming Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostatitis therapeutics pipeline - Phase III drug candidate is expected to commercialize in the coming years

  2. Prostatitis Therapeutics Pipeline Prostatitis therapeutics pipeline in 2017 The study analyzed that the prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development. Prostatitis is an infection or inflammation of the prostate gland that can lead to various syndromes with varying clinical features. The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The National Institutes of Health (NIH) has recognized and defined a classification system for prostatitis in 1999. Access Report Summary with Detailed TOC on "Prostatitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/prostatitis-therapeutics-pipeline

  3. Prostatitis Therapeutics Pipeline Insights on pipeline segments According to the research findings, one drug candidate has entered the Phase III stage of development in prostatitis therapeutics pipeline.

  4. Prostatitis Therapeutics Pipeline Drug Candidates with Oral Route of Administration tend to Increase Patient Compliance The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini AcrafSpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase. Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini AcrafSpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.

  5. Prostatitis Therapeutics Pipeline Download report sample at: https://www.psmarketresearch.com/market-analysis/prostatitis-therapeutics-pipeline/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related